ArticleProceedings of the National Academy of Sciences of the United States of America2014
Prevention of influenza by targeting host receptors using engineered proteins.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Sialic acid-anchored haemagglutinin stalk neutralizing antibody M-SiaB enhances protection against highly pathogenic influenza H5N1/Texas/2024.Nature communications · 2026Article
- A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge.Infectious diseases and therapy · 2025Article
- Article
- Sialic acids in infection and their potential use in detection and protection against pathogens.RSC chemical biology · 2024Review
- Article
- Co-infection of the respiratory epithelium, scene of complex functional interactions between viral, bacterial, and human neuraminidases.Frontiers in microbiology · 2023Review
- Efficient TurboID-based proximity labelling method for identifying terminal sialic acid glycosylation in living cells.Acta biochimica et biophysica Sinica · 2022Article
- Activity of a Carbohydrate-Binding Module Therapy, Neumifil, against SARS-CoV-2 Disease in a Hamster Model of Infection.Viruses · 2022Article
- Review
- Targeting the glycans: A paradigm for host-targeted and COVID-19 drug design.Journal of cellular and molecular medicine · 2021Review
- The Pathogenesis and Immune Evasive Mechanisms of Equine Herpesvirus Type 1.Frontiers in microbiology · 2021Review
- Advances in the development of entry inhibitors for sialic-acid-targeting viruses.Drug discovery today · 2021Review
- Soluble klotho regulates TRPC6 calcium signalingFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- The use of plant lectins to regulate H1N1 influenza A virus receptor binding activity.PloS one · 2018Article
- Article
- Modeled structural basis for the recognition of α2-3-sialyllactose by soluble Klotho.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Sequence diversity of NanA manifests in distinct enzyme kinetics and inhibitor susceptibility.Scientific reports · 2016Article
- A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response.PLoS pathogens · 2016Article
- Why should cell biologists study microbial pathogens?Molecular biology of the cell · 2015Article
- Structural characterization of the carbohydrate-binding module of NanA sialidase, a pneumococcal virulence factor.BMC structural biology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
There is a need for new approaches for the control of influenza given the burden caused by annual seasonal outbreaks, the emergence of viruses with pandemic potential, and the development of resistance to current antiviral drugs. We show that multivalent biologics, engineered using carbohydrate-binding modules specific for sialic acid, mask the cell-surface receptor recognized by the influenza virus and protect mice from a lethal challenge with 2009 pandemic H1N1 influenza virus. The most promising biologic protects mice when given as a single 1-μg intranasal dose 7 d in advance of viral challenge. There also is sufficient virus replication to establish an immune response, potentially protecting the animal from future exposure to the virus. Furthermore, the biologics appear to stimulate inflammatory mediators, and this stimulation may contribute to their protective ability. Our results suggest that this host-targeted approach could provide a front-line prophylactic that has the potential to protect against any current and future influenza virus and possibly against other respiratory pathogens that use sialic acid as a receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.